The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them.

This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. The report focuses on three key segments of treatment:

• Antifungals (Allylamines, Azoles,Polyene Macrolides and Other Antifungals)
• Antibacterials (Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Carbopenems, Miscellaneous)
• Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors)

For each category and each subsegment, current market and forecast is provided. The report covers both currently marketed and late stage development products.. Revenues for each segment were generated using dollar sales for each product.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. As part of its coverage the report provides:

• Overview
• Description of Products on the Market
• Review of Products in Late Stage Development
• Market Estimates and Forecasts
• Competitive Analysis of Leading Providers
• Regional Breakdown of Antifungal, Antibacterial and Antiviral Market (US, Europe and Asia)
• Market Share of Antifungal, Antibacterial and Antiviral Market

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

Related Reports:

The Global Market for Medical Devices
Mar 1, 2010 - KLI2592223 - $1,500.00

What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline
Feb 1, 2010 - KLI2578515 - $4,200.00

2009 Worldwide Diagnostics Market Research Bundle
Oct 1, 2009 - KLI2401913 - $5,995.00

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
Oct 1, 2009 - KLI2384194 - $3,995.00

Implant-Based Dental Reconstruction: World Dental Implant and Bone Graft Market, 3rd Edition
Sep 1, 2009 - KLI2284095 - $3,500.00

Infectious Disease Diagnostic Markets
Aug 1, 2009 - KLI2391680 - $3,500.00

Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
Jun 1, 2009 - KLI2155319 - $3,995.00

H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)
May 1, 2009 - KLI2241990 - $800.00

The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition
May 1, 2009 - KLI2218043 - $3,995.00

Rx to OTC Switches 2009
May 1, 2009 - KLI2196300 - $3,500.00